See the DrugPatentWatch profile for Encorafenib
What year does encorafenib’s main patent expire in the US?
The patent-expiry year for encorafenib in the US depends on which specific patent (or exclusivity) you mean, because the marketed drug can be covered by multiple patents with different end dates. With only the drug name provided, there isn’t enough information to identify the correct patent and its exact US expiry year.
If you share either (a) the patent number, (b) the brand name (Braftovi) plus the patent number you’re looking at, or (c) the NDC/label strength and a link or screenshot to the listing you’re using, I can pinpoint the correct US expiry year for that specific right.
How do you figure out encorafenib’s US “patent expiry” date correctly?
People often mix up three different timelines:
- Patent expiry (the last date a specific patent still blocks generic competition).
- Orange Book “expiration” dates (patents listed for the product; these can differ by claim set and listing).
- Exclusivity (e.g., FDA exclusivity periods), which are not the same thing as patent term.
To determine the right year, you normally look up the US patents and exclusivity for the specific encorafenib product in the FDA’s Orange Book.
What’s the usual role of Braftovi (encorafenib) in US generic entry timing?
Generic entry timing in the US typically lines up with the first day a competitor can launch without infringing an unexpired patent and after meeting FDA application requirements. That means the “answer year” can differ depending on whether you’re asking for the last patent listed or the date when a generic could practically enter.
Quick next step
Reply with the patent number you’re trying to check (or confirm you mean Braftovi/encorafenib) and I’ll give you the exact US expiry year for that patent.